干扰素β-1a联合瑞德西韦与单用瑞德西韦治疗住院成人COVID-19的疗效比较:一项双盲、随机、安慰剂对照3期试验
该双盲、随机、安慰剂对照3期试验在5国63家医院纳入969例需住院的成人COVID-19下呼吸道感染患者,随机接受干扰素β-1a(44 μg皮下注射,隔日一次,最多4剂)联合瑞德西韦或安慰剂联合瑞德西韦。基线需高流量氧疗者联合干扰素β-1a不良事件和严重不良事件更多。结论:联合干扰素β-1a不优于单用瑞德西韦,高流量氧疗者可能更差。
要点
- 基线需高流量氧疗者,联合干扰素β-1a组不良事件69%(24/35)、严重不良事件60%(21/35),高于安慰剂组的39%(13/33)和24%(8/33)。
- 基线不需高流量氧疗者,联合组至少1件相关不良事件7%(33/442),高于安慰剂组3%(15/435)。
- 不推荐对住院COVID-19肺炎成人常规加用干扰素β-1a;尤其基线需高流量氧疗者应避免。
适用人群与场景
- 纳入:住院成人(年龄≥18岁)SARS-CoV-2感染RT-PCR阳性,且满足以下之一提示下呼吸道感染:影像学浸润、室内空气外周血氧饱和度≤94%、或需要补充氧疗。
- 排除:丙氨酸氨基转移酶或天冬氨酸氨基转移酶超过正常上限5倍、肾功能受损、对研究产品过敏、妊娠或哺乳、已接受机械通气、或预计72小时内出院或转院。
诊断标准与关键阈值
- 主要终点恢复定义:28天内八分类序数量表首次达到1、2或3分的那一天。
- 主要分析人群:改良意向治疗人群,即所有随机患者按实际临床严重程度分类。
- 安全性分析人群:所有至少接受一剂分配治疗的患者。
处置流程与药物剂量
- 所有患者接受静脉瑞德西韦:第1天200 mg负荷剂量,随后每日100 mg维持剂量,最多9天。
- 干扰素β-1a组:皮下注射44 μg干扰素β-1a,隔日一次,最多4剂,联合上述瑞德西韦方案。
- 安慰剂组:皮下注射安慰剂,隔日一次,最多4剂,联合上述瑞德西韦方案。
- 随机化按研究 sites 和入组时疾病严重程度分层。
红旗征与不能漏的情况
- 基线需高流量氧疗者,联合干扰素β-1a组不良事件69%(24/35)、严重不良事件60%(21/35),高于安慰剂组39%(13/33)和24%(8/33),提示该亚组应避免联合干扰素β-1a。
- 基线不需高流量氧疗者,联合组至少1件相关不良事件7%(33/442)vs 安慰剂组3%(15/435),需警惕相关不良事件。
研究设计与关键结果
- 研究类型:双盲、随机、安慰剂对照3期试验,63家医院,5国(日本、墨西哥、新加坡、韩国、美国),969例随机(干扰素β-1a联合瑞德西韦组487例,安慰剂联合瑞德西韦组482例)。
- 基线不需高流量氧疗者相关不良事件:联合组7%(33/442)vs 安慰剂组3%(15/435);需高流量氧疗者:联合组不良事件69%(24/35)、严重不良事件60%(21/35),安慰剂组39%(13/33)和24%(8/33)。
证据类型、等级与局限
- 证据类型:随机、双盲、安慰剂对照3期试验。
- 局限:部分亚组样本量小(如高流量氧疗亚组联合组35例、安慰剂组33例);至恢复时间95%CI不可估计;开放标签瑞德西韦(所有患者均接受且未设盲);未提及证据等级分级。
对床旁实践的改变
- 住院COVID-19肺炎成人不应常规在瑞德西韦基础上加用干扰素β-1a,因至恢复时间和28天死亡率均无改善。
- 基线需高流量氧疗的患者应避免使用干扰素β-1a联合瑞德西韦,因该亚组不良事件和严重不良事件更高。
- 基线不需高流量氧疗者使用联合方案时需注意相关不良事件发生率高于安慰剂(7% vs 3%)。
指南或共识出处
- 原文未提及指南或共识名称;试验注册号ClinicalTrials.gov NCT04492475;资助:美国国家过敏和传染病研究所(NIAID)。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Functional impairment of interferon, a natural antiviral component of the immune system, is associated with the pathogenesis and severity of COVID-19. We aimed to compare the efficacy of interferon beta-1a in combination with remdesivir compared with remdesivir alone in hospitalised patients with COVID-19.
METHODS: We did a double-blind, randomised, placebo-controlled trial at 63 hospitals across five countries (Japan, Mexico, Singapore, South Korea, and the USA). Eligible patients were hospitalised adults (aged ≥18 years) with SARS-CoV-2 infection, as confirmed by a positive RT-PCR test, and who met one of the following criteria suggestive of lower respiratory tract infection: the presence of radiographic infiltrates on imaging, a peripheral oxygen saturation on room air of 94% or less, or requiring supplemental oxygen. Patients were excluded if they had either an alanine aminotransferase or an aspartate aminotransferase concentration more than five times the upper limit of normal; had impaired renal function; were allergic to the study product; were pregnant or breast feeding; were already on mechanical ventilation; or were anticipating discharge from the hospital or transfer to another hospital within 72 h of enrolment. Patients were randomly assigned (1:1) to receive intravenous remdesivir as a 200 mg loading dose on day 1 followed by a 100 mg maintenance dose administered daily for up to 9 days and up to four doses of either 44 μg interferon beta-1a (interferon beta-1a group plus remdesivir group) or placebo (placebo plus remdesivir group) administered subcutaneously every other day. Randomisation was stratified by study site and disease severity at enrolment. Patients, investigators, and site staff were masked to interferon beta-1a and placebo treatment; remdesivir treatment was given to all patients without masking. The primary outcome was time to recovery, defined as the first day that a patient attained a category 1, 2, or 3 score on the eight-category ordinal scale within 28 days, assessed in the modified intention-to-treat population, defined as all randomised patients who were classified according to actual clinical severity. Safety was assessed in the as-treated population, defined as all patients who received at least one dose of the assigned treatment. This trial is registered with ClinicalTrials.gov, NCT04492475.
FINDINGS: Between Aug 5, 2020, and Nov 11, 2020, 969 patients were enrolled and randomly assigned to the interferon beta-1a plus remdesivir group (n=487) or to the placebo plus remdesivir group (n=482). The mean duration of symptoms before enrolment was 8·7 days (SD 4·4) in the interferon beta-1a plus remdesivir group and 8·5 days (SD 4·3) days in the placebo plus remdesivir group. Patients in both groups had a time to recovery of 5 days (95% CI not estimable) (rate ratio of interferon beta-1a plus remdesivir group vs placebo plus remdesivir 0·99 [95% CI 0·87-1·13]; p=0·88). The Kaplan-Meier estimate of mortality at 28 days was 5% (95% CI 3-7%) in the interferon beta-1a plus remdesivir group and 3% (2-6%) in the placebo plus remdesivir group (hazard ratio 1·33 [95% CI 0·69-2·55]; p=0·39). Patients who did not require high-flow oxygen at baseline were more likely to have at least one related adverse event in the interferon beta-1a plus remdesivir group (33 [7%] of 442 patients) than in the placebo plus remdesivir group (15 [3%] of 435). In patients who required high-flow oxygen at baseline, 24 (69%) of 35 had an adverse event and 21 (60%) had a serious adverse event in the interferon beta-1a plus remdesivir group compared with 13 (39%) of 33 who had an adverse event and eight (24%) who had a serious adverse event in the placebo plus remdesivir group.
INTERPRETATION: Interferon beta-1a plus remdesivir was not superior to remdesivir alone in hospitalised patients with COVID-19 pneumonia. Patients who required high-flow oxygen at baseline had worse outcomes after treatment with interferon beta-1a compared with those given placebo.
FUNDING: The National Institute of Allergy and Infectious Diseases (USA).
参考来源
- Kalil AC, Mehta AK, Patterson TF, et al. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021. PMID: 34672949. doi:10.1016/S2213-2600(21)00384-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。